RhumbLine Advisers
VKTX icon

RhumbLine Advisers’s Viking Therapeutics VKTX Stock Holding History

RhumbLine Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.46M Sell
114,211
-5,891
-5% -$190K ﹤0.01% 1535
2026
Q1 		$3.91M Buy
120,102
+439
+0.4% +$14.1K ﹤0.01% 1522
2025
Q4 		$4.21M Buy
119,663
+5,902
+5% +$209K ﹤0.01% 1483
2025
Q3 		$2.99M Sell
113,761
-772
-0.7% -$23K ﹤0.01% 1692
2025
Q2 		$3.04M Sell
114,533
-14,662
-11% -$386K ﹤0.01% 1663
2025
Q1 		$3.12M Sell
129,195
-1,032
-0.8% -$32.6K ﹤0.01% 1602
2024
Q4 		$5.24M Sell
130,227
-218
-0.2% -$12.4K ﹤0.01% 1397
2024
Q3 		$8.26M Buy
130,445
+3,187
+3% +$187K 0.01% 1160
2024
Q2 		$6.75M Sell
127,258
-16,845
-12% -$1.1M 0.01% 1230
2024
Q1 		$11.8M Buy
144,103
+14,911
+12% +$663K 0.01% 967
2023
Q4 		$2.4M Sell
129,192
-1,696
-1% -$22.2K ﹤0.01% 1819
2023
Q3 		$1.45M Buy
130,888
+3,059
+2% +$43.8K ﹤0.01% 2017
2023
Q2 		$2.07M Buy
+127,829
New +$2.68M ﹤0.01% 1888
2022
Q2 		– Sell
-92,483
Closed -$277K – 3243
2022
Q1 		$277K Sell
92,483
-16,399
-15% -$58.8K ﹤0.01% 2666
2021
Q4 		$501K Sell
108,882
-646
-0.6% -$3.62K ﹤0.01% 2509
2021
Q3 		$688K Buy
109,528
+3,378
+3% +$20.9K ﹤0.01% 2406
2021
Q2 		$636K Sell
106,150
-8,601
-7% -$51.1K ﹤0.01% 2444
2021
Q1 		$726K Sell
114,751
-5,510
-5% -$38.8K ﹤0.01% 2324
2020
Q4 		$677K Buy
120,261
+13,578
+13% +$82.2K ﹤0.01% 2314
2020
Q3 		$621K Sell
106,683
-14,089
-12% -$97K ﹤0.01% 2187
2020
Q2 		$871K Buy
120,772
+11,414
+10% +$75.8K ﹤0.01% 2099
2020
Q1 		$512K Buy
109,358
+8,750
+9% +$53.8K ﹤0.01% 2153
2019
Q4 		$807K Buy
100,608
+986
+1% +$7.19K ﹤0.01% 2175
2019
Q3 		$685K Buy
99,622
+7,803
+8% +$58K ﹤0.01% 2209
2019
Q2 		$762K Buy
91,819
+14,062
+18% +$120K ﹤0.01% 2176
2019
Q1 		$773K Buy
77,757
+5,017
+7% +$42K ﹤0.01% 2147
2018
Q4 		$556K Buy
72,740
+27,799
+62% +$332K ﹤0.01% 2245
2018
Q3 		$783K Buy
44,941
+3,304
+8% +$39.3K ﹤0.01% 2105
2018
Q2 		$395K Buy
+41,637
New +$277K ﹤0.01% 2410

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

RhumbLine Advisers's VKTX Position: Q2 2026 in Review

RhumbLine Advisers reduced its Viking Therapeutics (VKTX) stake by 4.9% in Q2 2026, selling an estimated $190K and leaving 114,211 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

RhumbLine Advisers first reported a position in VKTX in Q2 2018 and has held it in 29 quarters since. The position peaked at $11.8M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • RhumbLine Advisers held 114,211 shares of Viking Therapeutics worth $4.46M as of Q2 2026.
  • RhumbLine Advisers sold 5,891 Viking Therapeutics shares in Q2 2026, an estimated $190K.
  • Viking Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1535 holding.
  • RhumbLine Advisers first reported a position in Viking Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • RhumbLine Advisers's Viking Therapeutics position peaked at $11.8M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.